40 related articles for article (PubMed ID: 9166489)
21. Taxol: initial Israeli experience with a novel anticancer agent.
Sulkes A; Beller U; Peretz T; Shacter J; Hornreich G; McDaniel C; Winograd B
Isr J Med Sci; 1994 Jan; 30(1):70-8. PubMed ID: 7908013
[TBL] [Abstract][Full Text] [Related]
22. The taxanes: dosing and scheduling considerations.
Rowinsky EK
Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):7-19. PubMed ID: 9110338
[TBL] [Abstract][Full Text] [Related]
23. [Reduction of adverse reactions of anticancer agents with altered dose and schedule].
Horikoshi N
Nihon Rinsho; 2003 Jun; 61(6):1021-4. PubMed ID: 12806954
[TBL] [Abstract][Full Text] [Related]
24. Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer.
Einzig AI
Ann Oncol; 1994; 5 Suppl 6():S29-32. PubMed ID: 7865430
[TBL] [Abstract][Full Text] [Related]
25. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
Synold TW; Doroshow JH
J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
Danesi R; Conte PF; Del Tacca M
Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
[TBL] [Abstract][Full Text] [Related]
27. Short versus long duration infusions of paclitaxel for any adenocarcinoma.
Williams C; Collingwood M; Simera I; Grafton C
Cochrane Database Syst Rev; 2003; (1):CD003911. PubMed ID: 12535492
[TBL] [Abstract][Full Text] [Related]
28. Infusional therapy with alkylating agents.
Jones RB
J Infus Chemother; 1996; 6(2):74-81. PubMed ID: 8809653
[TBL] [Abstract][Full Text] [Related]
29. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
Cormio G; Di Vagno G; Melilli GA; Cazzolla A; Di Gesù G; Carriero C; Cramarossa D; Loverro G; Selvaggi L
J Chemother; 1999 Oct; 11(5):407-9. PubMed ID: 10632389
[TBL] [Abstract][Full Text] [Related]
30. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
31. A preliminary risk-benefit assessment of paclitaxel.
Bitton RJ; Figg WD; Reed E
Drug Saf; 1995 Mar; 12(3):196-208. PubMed ID: 7619331
[TBL] [Abstract][Full Text] [Related]
32. Theoretical and practical aspects of paclitaxel scheduling.
Gianni L
Ann Oncol; 1995 Nov; 6(9):861-3. PubMed ID: 8624286
[No Abstract] [Full Text] [Related]
33. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
34. Single-agent paclitaxel for the treatment of breast cancer: an overview.
Hortobagyi GN; Holmes FA
Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
[TBL] [Abstract][Full Text] [Related]
35. Treatment of patients with upper gastrointestinal carcinomas.
Ajani JA
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
[TBL] [Abstract][Full Text] [Related]
36. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel dose intensity.
Reed E; Bitton R; Sarosy G; Kohn E
J Infus Chemother; 1996; 6(2):59-63. PubMed ID: 8809650
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
